HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intestinal cancer risk in Crohn's disease: a meta-analysis.

AbstractAIM OF THE STUDY:
To clarify the intestinal cancer risk in Crohn's disease (CD).
METHODS:
20 clinical studies (1965-2008) with a total of 40,547 patients with Crohn's disease-associated cancer (CDAC) were included in the meta-analysis ("inverse variance weighted" method).
RESULTS:
The incidence of CDAC in any CD patient was 0.8/1,000 person years duration (pyd) (CI, 0.6-1.0). The incidences of different carcinomas were: colorectal cancer 0.5/1,000 pyd (CI, 0.3-0.6), small bowel carcinoma 0.3/1,000 pyd (CI, 0.1-0.5), and cancers arising from CD-associated fistulae 0.2/1,000 pyd (CI, 0.0-0.4). Compared to the incidence in an age-matched standard population, the risk of colorectal cancer was increased by factor 2-3 and of small bowel cancer by factor 18.75, respectively. Mean patient age at diagnosis of CD-associated colorectal cancer was 51.5 years, thus 20 years earlier than in a standard population. The mean duration of CD until diagnosis of CDAC was 18.3 years. Duration of CD, age at diagnosis of CD, and anatomical area of CD involvement had no significant influence on cancer incidence.
CONCLUSIONS:
CD is a risk factor for colorectal cancer, small bowel cancer, and fistula cancer; however, compared to ulcerative colitis, cancer risk is moderate.
AuthorsMike Georg Laukoetter, Rudolf Mennigen, C Mareike Hannig, Nani Osada, Emile Rijcken, Thorsten Vowinkel, Christian F Krieglstein, Norbert Senninger, Christoph Anthoni, Matthias Bruewer
JournalJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (J Gastrointest Surg) Vol. 15 Issue 4 Pg. 576-83 (Apr 2011) ISSN: 1873-4626 [Electronic] United States
PMID21152994 (Publication Type: Journal Article, Meta-Analysis)
Topics
  • Adult
  • Crohn Disease (complications)
  • Humans
  • Incidence
  • Intestinal Neoplasms (diagnosis, epidemiology, etiology)
  • Middle Aged
  • Prevalence
  • United Kingdom (epidemiology)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: